Harbour makes $90M upfront deal with Bristol Myers for new antibodies
海港生物医药与百时美施贵宝达成首付款9,000万美元的新型抗体合作交易

Bristol Myers Squibb is the latest large pharma to tap into the speed and efficiency of drug R&D in China.
百时美施贵宝成为最新一家借力manbetx3.0 快速高效药物研发的大型制药公司。